|
1
|
Chen W, Zhang S and Zou X: Evaluation on
the incidence, mortality and tendency of lung cancer in China.
Thoracic Cancer. 1:35–40. 2010. View Article : Google Scholar
|
|
2
|
Jazieh AR, Bamefleh H, Demirkazik A, et
al: MENA Lung Cancer Regional Guidelines Committee: Modification
and implementation of NCCN guidelines on non-small cell lung cancer
in the Middle East and North Africa region. J Natl Compr Canc Netw.
8(Suppl 3): S16–S21. 2010.PubMed/NCBI
|
|
3
|
Li J, Li ZN, Yu LC, et al: Association of
expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients
with locally advanced non-small cell lung cancer who received
neoadjuvant chemotherapy. Lung Cancer. 69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosell R, Danenberg K, Alberola V, et al:
Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA
expression and survival in gemcitabine/cisplatin-treated advanced
non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peters GJ, Backus HH, Freemantle S, et al:
Induction of thymidylate synthase as a 5-fluorouracil resistance
mechanism. Biochim biophys Acta. 1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Azuma K, Sasada T, Kawahara A, et al:
Expression of ERCC1 and class III beta-tubulin in non-small cell
lung cancer patients treated with carboplatin and paclitaxel. Lung
Cancer. 64:326–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burkhart CA, Kavallaris M and Band Horwitz
S: The role of beta-tubulin isotypes in resistance to antimitotic
drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
|
|
8
|
Flagella M, Bui S, Zheng Z, et al: A
multiplex branched DNA assay for parallel quantitative gene
expression profiling. Anal Biochem. 352:50–60. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ren GJ, Zhao YY, Zhu YJ, et al: Tumor gene
mutations and messenger RNA expression: correlation with clinical
response to icotinib hydrochloride in non-small cell lung cancer.
Chin Med J (Engl). 124:19–25. 2011.PubMed/NCBI
|
|
10
|
Crinò L, Weder W, van Meerbeeck J and
Felip E: ESMO Guidelines Working Group: Early stage and locally
advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21(Suppl 5): 103–115. 2010. View Article : Google Scholar
|
|
11
|
Zheng Z, Chen T, Li X, et al: DNA
synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J
Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee KH, Min HS, Han SW, et al: ERCC1
expression by immunohistochemistry and EGFR mutations in resected
non-small cell lung cancer. Lung Cancer. 60:401–407. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gurubhagavatula S, Liu G, Park S, et al:
XPD and XRCC1 genetic polymorphisms are prognostic factors in
advanced non-small-cell lung cancer patients treated with platinum
chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou W, Gurubhagavatula S, Liu G, et al:
Excision repair cross-complementation group 1 polymorphism predicts
overall survival in advanced non-small cell lung cancer patients
treated with platinum-based chemotherapy. Clin Cancer Res.
10:4939–4943. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davidson JD, Ma L, Flagella M, et al: An
increase in the expression of ribonucleotide reductase large
subunit 1 is associated with gemcitabine resistance in non-small
cell lung cancer cell lines. Cancer Res. 64:3761–3766. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ceppi P, Volante M, Novello S, et al:
ERCC1 and RRM1 gene expressions but not EGFR are predictive of
shorter survival in advanced non-small-cell lung cancer treated
with cisplatin and gemcitabine. Ann Oncol. 17:1818–25. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sève P, Reiman T, Lai R, et al: Class III
beta-tubulin is a marker of paclitaxel resistance in carcinomas of
unknown primary site. Cancer Chemother Pharmacol. 60:27–34. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sève P and Dumontet C: Is class III
beta-tubulin a predictive factor in patients receiving
tubulin-binding agents? Lancet Oncol. 9:168–75. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ceppi P, Rapa I, Lo Iacono M, et al:
Expression and pharmacological inhibition of thymidylate synthase
and Src kinase in nonsmall cell lung cancer. Int J Cancer.
130:1777–1786. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grimminger PP, Schneider PM, Metzger R, et
al: Low thymidylate synthase, thymidine phosphorylase, and
dihydropyrimidine dehydrogenase mRNA expression correlate with
prolonged survival in resected non-small-cell lung cancer. Clin
Lung Cancer. 11:328–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakagawa T, Otake Y, Yanagihara K, et al:
Expression of thymidylate synthase is correlated with proliferative
activity in non-small cell lung cancer (NSCLC). Lung Cancer.
43:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng Z, Li X, Schell MJ, et al:
Thymidylate synthase in situ protein expression and survival in
stage I nonsmall-cell lung cancer. Cancer. 112:2765–73. 2008.
View Article : Google Scholar : PubMed/NCBI
|
